Carfilzomib, Proteasome inhibitor (TBI1477)

Description

Product Details

Formal Name: (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]- L-Phenylalaninamide

Alternate Names: PR-171

Molecular Formula: C₄₀H₅₇N₅O₇

Formula Weight: 719.93

CAS Number: 868540-17-4

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 80 mg/ml) or in Ethanol (up to 25 mg/ml).

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

Proteasome inhibitor

 

Functions

A potent and irreversible proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with carfilzomib results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis. Effective against multiple myeloma. Active in vivo.

 

Application Procedures

First dissolved in DMSO (up to 80 mg/ml) or in Ethanol (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20° for up to 1 week.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI1477_Carfilzomib

MSDS:

TBI1477_Carfilzomib_MSDS_2024